Skip to content

Contact_Dermatitis: add the two missing TG 442D methods, cite the guideline - #18225

Open
gingin77 wants to merge 1 commit into
mainfrom
contact-dermatitis-tg442d-models
Open

gingin77 wants to merge 1 commit into
mainfrom
contact-dermatitis-tg442d-models

Conversation

@gingin77

Copy link
Copy Markdown
Member

TG 442D describes five test methods for keratinocyte activation. This entry carried three. Epi2SensA and α-Sens® are now curated, and the three already here cite the guideline for their own regulatory standing instead of quoting a research paper that was only mentioning it.

Stacked on #18224, which makes OECDTG:442D citable. This PR's guideline citations do not resolve without it, so it targets that branch; GitHub will retarget it to main when #18224 merges.

The citation that was wrong

KeratinoSens's OECD-acceptance evidence was a quote_role: BACKGROUND quote from the introduction of the LuSens inter-laboratory paper — a workaround for the guideline not being citable, which attributes a regulatory statement to a study that did not make it. It now quotes the guideline's own validation statement. LuSens and EpiSensA had no guideline citation at all and now have one each.

The two new methods

Epi2SensA is the second reconstructed-epidermis marker-gene method: the same four genes as EpiSensA, read in EpiDerm (EPI-200) rather than LabCyte EPI-MODEL24, with a two-marker positive call and a 60% rather than 80% viability floor. That two-marker rule is recorded as a limitation of its link, not just a procedural detail — a positive can be called on the inflammatory pair alone, so it does not establish that the cytoprotective arm the node carries responded.

α-Sens® is the third ARE-Nrf2 luciferase method and the only one with an internal viability control: Firefly Luc+ under a quadruplicated AKR1C2 ARE plus TK-driven Renilla in the same cells, serum-free. Its originating paper reports clear positives for phenyl benzoate and eugenol, which KeratinoSens and LuSens call falsely negative — which is why it is a separate model rather than a third spelling of the same one.

Two smaller corrections

LuSens gained a SPECIES_MISMATCH divergence. Its reporter's regulatory element is the rat NQO1 ARE read in a human cell, where the other two luciferase methods use the human AKR1C2 ARE. That was recorded only in prose. Qualifying rather than invalidating — the transcription factor and pathway are the human cell's own, and only the binding site is of rat origin.

The EpiSensA link said its ATF3/IL-8 arm had no node in this entry. It now says why Keratinocyte inflammasome danger signalling is not that node: that node is scoped to NLRP3/ASC assembly with caspase-1 activation, and its own notes record the proximal route into the inflammasome as uncurated, so hanging a P2X7-dependent gene-induction readout there would assert the route the node declines to claim.

Relationship to #15944

Worth stating, because it is easy to misread. #15944 asks for a model inventory across in chemico, in vitro, tissue, animal and computational, and most of that list is already curated here. Epi2SensA and α-Sens® are not on it — they are appendices IC and ID of the 2026 edition of TG 442D, which postdates that issue. So this is not a slice of #15944's inventory, and it does not touch that issue's mechanistic half or its targets outside this entry.

One alignment is worth noting: #15944 asks that each model carry a stated inference, since "a reporter for one transcription factor is not the key event." The typed divergences here are that requirement made structural.

Whoever curates #15944 should not re-add these two methods.

Validation

just validate: 195 snippets, 218 titles, 0 issues. Terms pass. Ten per-file gates clean, plus the history record and the nine whole-KB ratchets.

Refs #16338

🤖 Generated with Claude Code

@ai4c-reviewer

ai4c-reviewer Bot commented Nov 15, 2026 •

Copy link
Copy Markdown

Claude encountered an error after 0s —— View job


I'll analyze this and get back to you.

@gingin77
gingin77 force-pushed the contact-dermatitis-tg442d-models branch from ad572bf to 4340e5f Compare November 15, 2026 20:54
@ai4c-reviewer

ai4c-reviewer Bot commented Nov 15, 2026 •

Copy link
Copy Markdown

Claude finished @gingin77's task in 3m 32s —— View job


Review complete — approved ✅

  • Read the diff and all four changed files
  • Re-verified every new snippet against references_cache/ with the real normalizer
  • Ran count-verified-snippets (195/195), check-entity-refs, check-snippet-grading
  • Checked divergences, scale slots and model types against the guideline record
  • Submitted an APPROVE review

Verdict: approved. All 13 new guideline/paper quotes are exact, every explanation traces to the paragraph it claims (paras 57, 213, 243, 255, 279, 303, 315, 333 of OECDTG_442D.md), the KeratinoSens citation repair removes a regulatory statement wrongly attributed to a research paper's introduction, and the typed divergences — Epi2SensA's two-marker PROXY_QUANTITY and LuSens's rat-ARE SPECIES_MISMATCH — carry real information rather than restating fidelity. Scope is clean: four files, no derived artifacts, no merge damage.

Three 🔵 suggestions, none blocking: the incidental full_text_attempted: true line added to a tracked cache file, an unquoted "only one with an internal viability control" claim in the α-Sens description, and a provenance note for the developer-run phenyl benzoate / eugenol comparison. Full detail in the review.
· branch contact-dermatitis-tg442d-models

@ai4c-reviewer ai4c-reviewer Bot left a comment

Copy link
Copy Markdown

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Review summary

  • Schema validation would pass (entity refs clean; snippet audit 195/195; snippet-grading ratchet clean)
  • All references verified as real and cached (OECDTG:442D, DOI:10.3390/toxics14040295, PMID:32335162)
  • Evidence snippets are exact quotes — every new snippet re-verified against the cached body with the real normalizer
  • Ontology terms correct and specific (no new term bindings in this PR)
  • evidence_source classifications correct
  • No pathophysiology bundling (no new pathophysiology nodes; this is a model-layer addition)
  • Scope: 4 files, all in scope; no merge-conflict damage, no derived files

Verification run locally: just count-verified-snippets kb/disorders/Contact_Dermatitis.yaml → 195/195; just check-entity-refs → OK; just check-snippet-grading → no new divergences. I also re-checked every new snippet independently against references_cache/ with SupportingTextValidator.normalize_text — all new guideline/paper quotes are exact. The one snippet in the file that does not match its cached abstract (PMID:21742781, line 435) is pre-existing, outside this diff, and matches full text; not this PR's backlog to carry.

Content checks

The KeratinoSens citation repair is the most valuable part of this PR. The old item attributed "accepted under OECD TG 442D" to the introduction of the LuSens inter-laboratory paper. It now quotes the guideline's own VRM sentence (para 57), graded REVIEW_SYNTHESIS — the right value for a regulatory consensus document restating validation work done elsewhere.

Each new fact traces to the paragraph the explanation claims. Spot-checked against references_cache/OECDTG_442D.md:

  • LuSens rat NQO1 ARE, and the direct-vs-indirect Nrf2 dependence → para 213 (the guideline's own VMR spelling is preserved verbatim and the explanation says so). directness: INDIRECT is the right grade for a statement that the dependence is only indirectly demonstrated for this method.
  • Epi2SensA's two-marker prediction model and 60% viability floor → para 279; the 1 h + 5 h versus 6 h exposure likewise.
  • EpiSensA/Epi2SensA VRM standing → para 243; the marker-gene arm split → the guideline's own sentence.
  • α-Sens quadruplicated ARE / Luc+ / TK-Renilla → para 333; AKR1C2 identity with the VRM → same paragraph; 83% / 84% / 79% against 112 human reference substances → para 303, quoted exactly including the DASS framing.
  • The limitations are not invented: "limited metabolic capability of the cell line" and the lysine-reactivity caveat are para 315 for α-Sens; the RhE "similar metabolic capacity … further confirmation is still needed" and the exposure-window point are para 255 for Epi2SensA.

The divergences do real work rather than restating fidelity. The Epi2SensA PROXY_QUANTITY entry is the right call: under a two-marker rule a positive can be carried by ATF3 + IL-8 alone, so the result does not establish that the cytoprotective arm this node carries responded — a looser proxy than EpiSensA's single-marker call. Recording that as a typed divergence rather than a procedural footnote is what the taxonomy is for. The α-Sens note that quadruplication amplifies the reporter without changing the endogenous response it stands in for is a genuine distinction from KeratinoSens's single-copy construct.

The LuSens SPECIES_MISMATCH addition is correct and correctly graded. QUALIFYING is right — the transcription factor and the pathway are the human cell's own, and only the binding site is of rat origin — and it is the one structural fact separating LuSens from the other two luciferase methods.

Scale slots are coherent. The target node Hapten-driven keratinocyte electrophile sensing is CELLULAR; Epi2SensA's TISSUE is model-above-target (unremarkable, no caveat required) and α-Sens's CELLULAR is equal. Both match how EpiSensA and KeratinoSens are already recorded, and experimental_model_type follows the neighbouring records (OTHER for RhE with the reason in notes, CELL_LINE for the luciferase methods).

The EpiSensA description fix is the right resolution, not a dodge. Saying why Keratinocyte inflammasome danger signalling is not the node for the ATF3/IL-8 arm — that node is scoped to NLRP3/ASC assembly with caspase-1, and its own notes decline to claim the proximal route — is better than either hanging the readout there or leaving "no node for this".

🔵 Suggestions (non-blocking)

  1. references_cache/PMID_32335162.md gains a full_text_attempted: true frontmatter line. CLAUDE.md treats a tracked cache file modified by a validation run as a bug to report rather than a change to commit. Here the field is accurate and nothing else in the file moved, so it is harmless — but worth confirming it came from a deliberate just fetch-reference rather than an incidental validator write-back, and dropping the hunk if it was the latter.
  2. The α-Sens description says it is "the only one with an internal viability control". Para 333 supports it ("allows simultaneous measurement of ARE-mediated activity and cell viability … in the same cells"), but that sentence is not among the quoted snippets. Since it is the stated reason for carrying α-Sens as a separate model, quoting it would make the claim checkable from the entry itself.
  3. The phenyl benzoate / eugenol false-negative comparison comes from the originating paper's own abstract (correctly IN_VITRO). A line in notes recording that this is the developer's own comparison against the other two methods rather than an independent head-to-head would help a later reader weigh it.

Deep-research cross-check

N/A. This is a targeted augmentation of an existing entry's experimental_models block from a guideline that became citable in the base branch, not a new entry, so the new-entry deep-research requirement does not apply. The PR body's statement that Epi2SensA and α-Sens are 2026-edition appendices and therefore outside #15944's inventory is consistent with the guideline record, and the note telling whoever picks up #15944 not to re-add them is the right thing to leave behind.

Approving.

@gingin77
gingin77 added this pull request to the merge queue Nov 16, 2026
@github-merge-queue
github-merge-queue Bot removed this pull request from the merge queue due to failed status checks Nov 16, 2026
Base automatically changed from oecd-tg-reference-source to main November 16, 2026 12:04
@gingin77
gingin77 force-pushed the contact-dermatitis-tg442d-models branch from 4340e5f to f069444 Compare November 16, 2026 12:05
@ai4c-reviewer

ai4c-reviewer Bot commented Nov 16, 2026 •

Copy link
Copy Markdown

Claude finished @gingin77's task in 2m 9s —— View job


Re-review complete: approved ✅

  • Find what changed since the last approval
  • Check new and changed snippets against the cache
  • Run gates
  • Submit review

The push was only a rebase onto main after #18224 merged. All four changed files have the same blob hashes as the version approved yesterday, so the content is the same. The guideline cache file (OECDTG_442D.md) now comes from main.

I re-ran these on the rebased tree:

  • just count-verified-snippets: 195/195
  • just check-entity-refs: OK
  • just check-snippet-grading: no new divergences

I submitted a new APPROVE review because the push had dropped the earlier one. The three optional 🔵 suggestions from the previous review still apply: the full_text_attempted line, quoting the α-Sens viability-control sentence, and a provenance note on the eugenol comparison.
· branch contact-dermatitis-tg442d-models

@ai4c-reviewer ai4c-reviewer Bot left a comment

Copy link
Copy Markdown

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Re-review after the rebase: approved

  • Schema validation would pass
  • All PMIDs verified as real (OECDTG:442D, DOI:10.3390/toxics14040295, PMID:32335162, all cached)
  • Evidence snippets are exact quotes (195/195 verified against the cache)
  • Ontology terms correct and specific (no new term bindings)
  • evidence_source classifications correct
  • No pathophysiology bundling (no new pathophysiology nodes)

This push only rebased the branch onto main after #18224 merged. The PR now targets main with one commit. All four changed files have the same blob hashes as the version approved yesterday:

  • Contact_Dermatitis.yaml 67b7495
  • the history record 0be61ba
  • DOI_10.3390_toxics14040295.md a8a0a8c
  • PMID_32335162.md 9e1d6e4

So the content is identical. references_cache/OECDTG_442D.md now comes from main, so the guideline citations resolve on the base branch.

I re-ran these on the rebased tree:

  • just count-verified-snippets: 195/195
  • just check-entity-refs: OK
  • just check-snippet-grading: no new divergences

The earlier review's three 🔵 suggestions still apply and are still optional:

  1. Confirm that the full_text_attempted: true line on PMID_32335162.md came from a deliberate fetch.
  2. Quote the paragraph 333 sentence on the internal viability control for α-Sens.
  3. Add a note that the phenyl benzoate / eugenol comparison is the developer's own.

…deline

TG 442D describes five test methods; this entry carried three. Epi2SensA and
α-Sens® are now curated, and the three already here cite the guideline for
their own regulatory standing rather than quoting a research paper that was
only mentioning it.

The replaced item is the clearest case. KeratinoSens's OECD-acceptance
evidence was a `quote_role: BACKGROUND` quote from the introduction of the
LuSens inter-laboratory paper — a workaround for the guideline not being
citable, which attributes a regulatory statement to a study that did not make
it. It now quotes the guideline's own VRM statement. LuSens and EpiSensA had
no guideline citation at all and now have one each.

Epi2SensA is the second RhE marker-gene method: the same four genes as
EpiSensA, read in EpiDerm (EPI-200) rather than LabCyte EPI-MODEL24, with a
two-marker positive call and a 60% rather than 80% viability floor. That
two-marker rule is recorded as a limitation of its link, not just a procedural
detail: a positive can be called on the inflammatory pair alone, so it does
not establish that the cytoprotective arm the node carries responded.

α-Sens® is the third ARE-Nrf2 luciferase method and the only one with an
internal viability control — Firefly Luc+ under a quadruplicated AKR1C2 ARE
plus TK-driven Renilla in the same cells, FBS-free. Its originating paper
reports clear positives for phenyl benzoate and eugenol, which KeratinoSens or
LuSens call falsely negative, which is why it is a separate model rather than a
third spelling of the same one.

LuSens gained a SPECIES_MISMATCH divergence. Its reporter's regulatory element
is the rat NQO1 ARE read in a human cell, where the other two luciferase
methods use the human AKR1C2 ARE; that was recorded only in prose. Qualifying
rather than invalidating — the transcription factor and pathway are the human
cell's own, and only the binding site is of rat origin.

The EpiSensA link said its ATF3/IL-8 arm had no node in this entry. It now says
why `Keratinocyte inflammasome danger signalling` is not that node: that node
is scoped to NLRP3/ASC assembly with caspase-1 activation, and its own notes
record the proximal route into the inflammasome as uncurated, so hanging a
P2X7-dependent gene-induction readout there would assert the route the node
declines to claim.

just validate: 195 snippets, 218 titles, 0 issues.

Refs #16338

Co-Authored-By: Claude Opus 5 <noreply@anthropic.com>
@gingin77
gingin77 force-pushed the contact-dermatitis-tg442d-models branch from f069444 to 2a09a0b Compare November 16, 2026 13:45
@ai4c-reviewer

ai4c-reviewer Bot commented Nov 16, 2026 •

Copy link
Copy Markdown

Claude finished @gingin77's task in 34s —— View job


Re-review: no new review needed, approval already on this commit ✅

  • Compare the current head with the last approved commit
  • Re-run the snippet audit
  • Decide on review status

This run was started by a synchronize event. The PR head is still 2a09a0b5, and that is the same commit the approval at 2026-11-16 12:14 UTC was given on. The four changed files have the same blob hashes as the reviewed version (for example Contact_Dermatitis.yaml is 67b7495). GitHub already shows the review decision as APPROVED, and the PR can be merged without conflicts. I did not submit another review, because a second approval on the same commit would add nothing.

just count-verified-snippets kb/disorders/Contact_Dermatitis.yaml still reports 195/195 snippets verified against the cache.

The three optional 🔵 suggestions from the first review still apply. None of them blocks merging:

  1. The full_text_attempted: true line added to references_cache/PMID_32335162.md.
  2. Quoting the paragraph 333 sentence that backs the α-Sens claim to be "the only one with an internal viability control".
  3. A notes line saying that the phenyl benzoate / eugenol comparison is the developers' own result, not an independent head-to-head study.
    · branch contact-dermatitis-tg442d-models

@ai4c-reviewer

ai4c-reviewer Bot commented Nov 16, 2026 •

Copy link
Copy Markdown

Claude finished @gingin77's task in 23s —— View job


Re-review: no new changes, approval still stands ✅

  • Compare the PR head with the last approved commit
  • Decide whether to review again

The PR head is 2a09a0b54. That is the same commit approved at 2026-11-16 12:14 UTC, after the rebase onto main once #18224 merged. This run was started by that same rebase push, so there is nothing new to review. The approval on the current head is still in place, so I have not submitted another one.

The diff against origin/main is still the same four files: the history record, Contact_Dermatitis.yaml, DOI_10.3390_toxics14040295.md, and the one-line PMID_32335162.md change.

The three optional 🔵 suggestions from the first review still apply, and none of them blocks merging:

  1. Check the full_text_attempted: true line in references_cache/PMID_32335162.md. If a validation run wrote it back by accident, drop it.
  2. The α-Sens® description says it has an internal viability control. Quote the sentence from paragraph 333 that supports this.
  3. Add a note in notes that the phenyl benzoate / eugenol comparison is the developers' own, not an independent head-to-head.
    · branch contact-dermatitis-tg442d-models

This branch has not been deployed

No deployments
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment

Labels

None yet

Projects

None yet

Development

Successfully merging this pull request may close these issues.

1 participant